使用临床验证的靶向测序面板检测儿童脑肿瘤脑脊液中的肿瘤来源游离DNA
本研究采集15例儿童原发性中枢神经系统肿瘤患者的17份脑脊液样本,用临床验证的UW-OncoPlex™平台测序脑脊液游离DNA,9/17(53%)样本检出肿瘤来源游离DNA,8/10(80%)提取样本量足够测序,所有体细胞突变和拷贝数变异与配对肿瘤组织一致,血浆和对照样本中未检出肿瘤来源游离DNA。
要点
- 脑脊液游离DNA在9/17(53%)样本中检出,8/10(80%)提取样本量足够测序。
- 所有体细胞突变和拷贝数变异在配对肿瘤组织中均检出,血浆和对照样本中未检出肿瘤来源游离DNA。
- 在少至200 µl脑脊液中,无细胞学恶性细胞证据时仍可检出肿瘤来源游离DNA改变。
核心结论
- 使用脑脊液游离DNA可在多种儿童脑肿瘤中检出临床相关基因组改变。
- 二代测序平台能够产生高比例的DNA改变,与组织分析的一致率为100%。
研究设计与样本
- 从15例儿童原发性中枢神经系统肿瘤患者采集17份脑脊液样本,采集方式为腰椎穿刺、脑室造瘘或手术。
主要发现
- 肿瘤类型包括髓母细胞瘤(n=7)、非典型畸胎样/横纹肌样瘤(n=2)、伴H3 K27改变的弥漫性中线胶质瘤(n=4)、毛细胞型星形细胞瘤(n=1)和多形性黄色星形细胞瘤(n=1)。
- 脑脊液游离DNA在9/17(53%)样本中检出,在8/10(80%)提取样本量足够测序。
- 所有体细胞突变和拷贝数变异在配对肿瘤组织中均检出,血浆样本和对照样本中未检出肿瘤来源游离DNA。
- 在少至200 µl脑脊液中,无细胞学恶性细胞证据时仍可检出肿瘤来源游离DNA改变。
- 检出若干临床相关改变,包括KIAA1549::BRAF融合。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Clinical sequencing of tumor DNA is necessary to render an integrated diagnosis and select therapy for children with primary central nervous system (CNS) tumors, but neurosurgical biopsy is not without risk. In this study, we describe cell-free DNA (cfDNA) in blood and cerebrospinal fluid (CSF) as sources for "liquid biopsy" in pediatric brain tumors. METHODS: CSF samples were collected by lumbar puncture, ventriculostomy, or surgery from pediatric patients with CNS tumors. Following extraction, CSF-derived cfDNA was sequenced using UW-OncoPlex™, a clinically validated next-generation sequencing platform. CSF-derived cfDNA results and paired plasma and tumor samples concordance was also evaluated. RESULTS: Seventeen CSF samples were obtained from 15 pediatric patients with primary CNS tumors. Tumor types included medulloblastoma (n = 7), atypical teratoid/rhabdoid tumor (n = 2), diffuse midline glioma with H3 K27 alteration (n = 4), pilocytic astrocytoma (n = 1), and pleomorphic xanthoastrocytoma (n = 1). CSF-derived cfDNA was detected in 9/17 (53%) of samples, and sufficient for sequencing in 8/10 (80%) of extracted samples. All somatic mutations and copy-number variants were also detected in matched tumor tissue, and tumor-derived cfDNA was absent in plasma samples and controls. Tumor-derived cfDNA alterations were detected in the absence of cytological evidence of malignant cells in as little as 200 µl of CSF. Several clinically relevant alterations, including a KIAA1549::BRAF fusion were detected. CONCLUSIONS: Clinically relevant genomic alterations are detectable using CSF-derived cfDNA across a range of pediatric brain tumors. Next-generation sequencing platforms are capable of producing a high yield of DNA alterations with 100% concordance rate with tissue analysis.
引用
- Ronsley R, Karvonen KA, Cole B, et al. Detection of tumor-derived cell-free DNA in cerebrospinal fluid using a clinically validated targeted sequencing panel for pediatric brain tumors. J Neurooncol. 2024. PMID: 38755519. doi:10.1007/s11060-024-04645-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。